12/5
07:00 am
bmea
Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
Medium
Report
Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
12/1
05:32 pm
bmea
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Medium
Report
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
12/1
04:22 pm
bmea
Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) [Yahoo! Finance]
Medium
Report
Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) [Yahoo! Finance]
12/1
04:10 pm
bmea
Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
Medium
Report
Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
12/1
04:05 pm
bmea
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
11/24
07:00 am
bmea
Biomea Fusion to Participate at Upcoming Investor Conferences
Neutral
Report
Biomea Fusion to Participate at Upcoming Investor Conferences
11/10
04:52 pm
bmea
Biomea Fusion (NASDAQ:BMEA) had its price target lowered by analysts at Citigroup Inc. from $7.00 to $6.00. They now have a "buy" rating on the stock.
Low
Report
Biomea Fusion (NASDAQ:BMEA) had its price target lowered by analysts at Citigroup Inc. from $7.00 to $6.00. They now have a "buy" rating on the stock.
11/10
07:00 am
bmea
Biomea Fusion to Participate at Jefferies London Healthcare Conference
Low
Report
Biomea Fusion to Participate at Jefferies London Healthcare Conference
11/5
08:45 am
bmea
Biomea Fusion (NASDAQ:BMEA) had its price target lowered by analysts at D. Boral Capital from $16.00 to $12.00. They now have a "buy" rating on the stock.
Medium
Report
Biomea Fusion (NASDAQ:BMEA) had its price target lowered by analysts at D. Boral Capital from $16.00 to $12.00. They now have a "buy" rating on the stock.
11/5
07:00 am
bmea
Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek® 2025
Medium
Report
Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek® 2025
11/4
04:05 pm
bmea
Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights
Medium
Report
Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights
10/30
08:00 am
bmea
Biomea Fusion to Present Poster Presentations at ObesityWeek®2025
Low
Report
Biomea Fusion to Present Poster Presentations at ObesityWeek®2025
10/27
08:44 am
bmea
Biomea Fusion (NASDAQ:BMEA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $16.00 price target on the stock.
Medium
Report
Biomea Fusion (NASDAQ:BMEA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $16.00 price target on the stock.
10/27
08:00 am
bmea
Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist
Medium
Report
Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist
10/21
07:46 pm
bmea
Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series [Yahoo! Finance]
Medium
Report
Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series [Yahoo! Finance]
10/21
07:05 pm
bmea
Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series
Medium
Report
Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series
10/7
01:26 pm
bmea
Biomea Fusion: Surging On Data, Sinking On Funding - I'm On The Sidelines [Seeking Alpha]
Medium
Report
Biomea Fusion: Surging On Data, Sinking On Funding - I'm On The Sidelines [Seeking Alpha]
10/7
08:00 am
bmea
Biomea Fusion Announces Pricing of Public Offering of Securities
High
Report
Biomea Fusion Announces Pricing of Public Offering of Securities
10/6
04:47 pm
bmea
Biomea Fusion Announces Proposed Public Offering of Securities [Yahoo! Finance]
High
Report
Biomea Fusion Announces Proposed Public Offering of Securities [Yahoo! Finance]
10/6
04:23 pm
bmea
Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations [Yahoo! Finance]
High
Report
Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations [Yahoo! Finance]
10/6
04:18 pm
bmea
Biomea Fusion Announces Proposed Public Offering of Securities
High
Report
Biomea Fusion Announces Proposed Public Offering of Securities
10/6
04:03 pm
bmea
Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations
High
Report
Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations
10/3
08:47 am
bmea
Biomea Fusion (NASDAQ:BMEA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $16.00 price target on the stock.
Neutral
Report
Biomea Fusion (NASDAQ:BMEA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $16.00 price target on the stock.
10/1
07:00 am
bmea
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
9/16
07:00 am
bmea
Biomea Fusion Presents Data Demonstrating Enhanced Preclinical Activity of Icovamenib in Combination with Semaglutide in Type 2 Diabetes (T2D) Animal Model at the 61st EASD Annual Meeting and Provides Additional Corporate Update
Medium
Report
Biomea Fusion Presents Data Demonstrating Enhanced Preclinical Activity of Icovamenib in Combination with Semaglutide in Type 2 Diabetes (T2D) Animal Model at the 61st EASD Annual Meeting and Provides Additional Corporate Update